Medical Cannabis for Chronic Pain — Switzerland 2026

Chronic pain is the most common indication for a cannabis prescription in Switzerland. Evidence, preparations, realistic dosing and how to get a serious, affordable prescription.

Chronic pain — especially neuropathic, palliative and musculoskeletal — is by far the most common cannabis indication in Swiss practice. Moderate evidence for neuropathic pain, weaker for back and fibromyalgia pain. Typical preparations: dronabinol drops, Bediol/Bedrocan flower, magistral oils. Start low, titrate slowly. Prescription: any licensed Swiss doctor. External consultation 190 CHF, CannabisClub members 50 CHF.

What the evidence says

Cochrane reviews 2018 and 2021: for neuropathic pain (nerve, MS, chemo, HIV), moderate evidence for cannabinoids — clinically relevant reduction in 20–30% of patients with acceptable side effects.

For nociceptive back and joint pain, evidence is weaker, but real benefit in off-label use — especially when opioids or NSAIDs aren't tolerated.

Preparations & dosing

Dronabinol drops: 2.5–10 mg THC per dose, 2–4×/day. Precise titration, common entry point.

Flower (Bediol 6/8, Bedrocan 22%): 0.1–0.5 g/day vaporised. Onset 5–10 min, useful for breakthrough pain.

Path to prescription

1. Gather diagnosis and existing reports (neurology, rheumatology, pain).

2. Consult a cannabis-trained doctor — external ~190 CHF, CannabisClub member 50 CHF flat.

FAQ

Does cannabis work for chronic pain?

For neuropathic pain: moderate evidence for clinically relevant reduction. For other chronic pain: weaker but valuable case by case — especially when opioids aren't tolerated.

Which cannabis preparation for pain?

Often dronabinol drops for baseline plus vaporised Bediol/Bedrocan for breakthrough pain. Sativex® mainly in MS.

Does cannabis replace opioids?

Not automatically, but many patients cut opioid use significantly. A sensible combined approach rather than full replacement.

Monthly cost of cannabis pain therapy?

Realistic: 300–1,000 CHF (preparation + consultations). Basic insurance rarely covers, prior authorisation worth pursuing with a strong diagnosis.

Cannabis for Chronic Pain — Prescription & Effect Switzerland 2026